Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies

Peffault De Latour, R, Mitchell, L, Brodsky, RA et al. (10 more authors) (2019) Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies. In: British Journal of Haematology. 59th Annual Scientific Meeting of the British Society for Hematology, 01-03 Apr 2019, Glasgow, UK. Wiley , p. 110.

Metadata

Authors/Creators:
Keywords: PNH
Dates:
  • Published (online): 27 March 2019
  • Published: March 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 30 Apr 2019 14:18
Last Modified: 30 Apr 2019 14:30
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1111/bjh.15854
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)